WASHINGTON - In a move that might decrease pressure for congressional action, the FDA plans to publicly assert its power to regulate the cloning of humans.

Philip Noguchi, director of the FDA's division of cellular and gene therapies, last week said that FDA has the authority, under regulations on cellular and tissue-based products promulgated last February, to require advance approval for therapies that involve more than minimal manipulation of cells or tissues.